A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-31. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
== Micellization and phase transitions == An important characteristic of poloxamer solutions is their temperature dependent self-assembling and thermo-gelling behavior. Concentrated aqueous solutions of poloxamers are liquid at low temperature and form a gel at higher temperature in a reversible process. The transitions that occur in these systems depend on the polymer composition (molecular weight and hydrophilic/hydrophobic molar ratio). At low temperatures and concentrations (below the critical micelle temperature and critical micelle concentration) individual block copolymers (unimers) are present in solution. Above these values, aggregation of individual unimers occurs in a process called micellization. This aggregation is driven by the dehydration of the hydrophobic polyoxypropylene block that becomes progressively less soluble as the polymer concentration or temperature increases. The aggregation of several unimers occurs to minimize the interactions of the PPO blocks with the solvent. Thus, the core of the aggregates is made from the insoluble blocks (polyoxypropylene) while the soluble portion (polyoxyethylene) forms the shell of the micelles.
== Mechanism of action == Interferon beta balances the expression of pro- and anti-inflammatory agents in the brain, and reduces the number of inflammatory cells that cross the blood brain barrier. Overall, therapy with interferon beta leads to a reduction of neuron inflammation. Moreover, it is also thought to increase the production of nerve growth factor and consequently improve neuronal survival. In vitro, interferon beta reduces production of Th17 cells which are a subset of T lymphocytes believed to have a role in the pathophysiology of MS.
=== Sequence data === Most of the work on substitution models has focused on DNA/RNA and protein sequence evolution. Models of DNA sequence evolution, where the alphabet corresponds to the four nucleotides (A, C, G, and T), are probably the easiest models to understand. DNA models can also be used to examine RNA virus evolution; this reflects the fact that RNA also has a four nucleotide alphabet (A, C, G, and U). However, substitution models can be used for alphabets of any size; the alphabet is the 20 proteinogenic amino acids for proteins and the sense codons (i.e., the 61 codons that encode amino acids in the standard genetic code) for aligned protein-coding gene sequences. In fact, substitution models can be developed for any biological characters that can be encoded using a specific alphabet (e.g., amino acid sequences combined with information about the conformation of those amino acids in three-dimensional protein structures). The majority of substitution models used for evolutionary research assume independence among sites (i.e., the probability of observing any specific site pattern is identical regardless of where the site pattern is in the sequence alignment). This simplifies likelihood calculations because it is only necessary to calculate the probability of all site patterns that appear in the alignment then use those values to calculate the overall likelihood of the alignment (e.g., the probability of three "GGGG" site patterns given some model of DNA sequence evolution is simply the probability of a single "GGGG" site pattern raised to the third power).
== Drawbacks == The drawbacks of the SMB are higher investment cost compared to single column operations, a higher complexity, as well as higher maintenance costs. But these drawbacks are effectively compensated by the better yield and a much lower solvent consumption as well as a much higher productivity compared to simple batch separations. For purifications, in particular the isolation of an intermediate single component or a fraction out of a multicomponent mixture, the SMB is not as ideally suited. Normally, a single SMB will separate only two fractions from each other, but a series or "train" of SMBs can perform multiple cuts and purify one or more products from a multi-component mixture. SMB is not readily suited for solvent gradients. Solvent gradient purification may be preferred for the purification of some biomolecules. A continuous chromatography technique to overcome the two fraction limit and to apply gradients is multicolumn countercurrent solvent gradient purification (MCSGP).
Sources: en.wikipedia.org
=== Cancer === Based on cell growth experiments, animal cancer models, and epidemiological studies, it appears that IGFBP-3 functions as a low-penetrance tumor suppressor gene. Dysregulation of IGFBP-3 has been implicated in many cancers. Downregulation of its tissue expression by promoter hypermethylation in some cancers, such as hepatoma and non-small cell lung cancer may be associated with poor patient outcome. However, consistent with the dual inhibitory and stimulatory roles of IGFBP-3 seen in cell culture, there are other cancer types, such as breast cancer, pancreatic cancer, and clear cell renal cell cancer in which high tissue IGFBP-3 expression has been linked to poor prognostic features or patient outcome. The mechanisms regulating these contrasting effects of IGFBP-3 in vivo are not well understood. Since IGFBP-3 is abundant in the bloodstream of healthy adults (typically 2–4 mg/L), and is largely stabilized by its complex formation with IGFs and ALS, it is unlikely that tumor-derived IGFBP-3 has a large influence on circulating levels. There have been many studies linking circulating IGFBP-3 levels to the presence, or risk, of various cancers, or to patient outcomes. but unequivocal conclusions have often been lacking. For example, high plasma IGFBP-3 levels were associated with a reduced prospective risk of colorectal cancer in women. but in a study including men and women, colon cancer risk was positively associated with plasma IGFBP-3, while there was no significant association for rectal cancer.
=== Micro BCA assay (for dilute solutions) === The BCA Micro BCA assay is a 3-component protocol which uses concentrated stocks of the Biuret reaction, BCA, and copper(II) reagents. It allows for an improved sensitivity of ~2 - 40 μg/mL vs 20 - 2000 μg/mL of the original BCA assay. However, it has a different, and generally speaking more sensitive, interference from non-protein components. Kits for the Micro BCA assay are available from at least two commercial vendors. Notably, the composition and use of a "Micro BCA Reagent and Protocol" was described in the original manuscript by Smith, and modern kits likely consist of an exact or highly similar formulation. The protocol consists of mixing Micro-Reagent B and the Copper Solution 25:1 to form Micro-Reagent C (MC), which is not shelf stable and should be freshly prepared, and then mixing MC 1:1 with Micro-Reagent A to produce the final (also unstable) assay working solution. Micro-Reagent A, Micro-Reagent B, and Copper Solution are stable indefinitely at room temperature. Micro-Reagent A (MA)
== Original restaurant == The first In-N-Out restaurant that opened in 1948 was demolished when Interstate 10 (then US 60/US 70/US 99, the Ramona Freeway, now the San Bernardino Freeway) was built from downtown Los Angeles to the San Gabriel Valley. The freeway runs over the original location. A new restaurant was completed in 1954 near the original Baldwin Park, California, location. It was closed in November 2004 and demolished on April 16, 2011, despite discussions about using it as an In-N-Out museum chronicling the origins and history of the company. In-N-Out built a replacement restaurant on the other side of the freeway next to the original In-N-Out University (opened in 1984). A new In-N-Out University was built on the property. The university building houses the training department, which was moved from Irvine, California. In addition, the company restaurant was moved from In-N-Out's Baldwin Park headquarters to the new lot, which holds the restaurant and university, less than a thousand feet away. In 2014, a replica of the first In-N-Out was built in Baldwin Park.
Collective bargaining through unions is one way that Australian workers achieve higher pay, but the Fair Work Act 2009 also creates a national minimum wage, and minimum scales depending on the workplace sector. FWA 2009 section 14 covers every "national system employer" that may be regulated by the federal constitution, and gaps were closed by all states referring their powers over industrial matters to the Commonwealth (except Western Australia). First, the Fair Work Commission sets a basic "national minimum wage" each year for all employees not covered by a specific "modern award", as a catch all safety net. From July 2023, the national minimum wage was $23.23 an hour, or $882.80 a week of 38 ordinary hours. Under section 284 its "minimum wage objective" must take into account improving productivity, competitiveness, inflation and employment growth, the need for gender equality, social inclusion through higher employment, the needs of the low paid, and fair wages for junior, training and disabled employees.
The three substrates of this enzyme are hydroxy-1,4-benzoquinone, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are hydroxyquinol and oxidised NAD+. This enzyme participates in the metabolism of 2,4,5-trichlorophenoxyacetic acid in the bacteria Burkholderia cepacia.
Sources: en.wikipedia.org
== Applications and examples == Exponential decay occurs in a wide variety of situations. Most of these fall into the domain of the natural sciences. Many decay processes that are often treated as exponential, are really only exponential so long as the sample is large and the law of large numbers holds. For small samples, a more general analysis is necessary, accounting for a Poisson process.
Because, as mentioned earlier, the amount of organic hydrogen produced from water varies between species, a model of trophic level related to absolute fractionation is difficult to make if the participating species are not known. Consistency in measuring the same tissues is also important, as different tissues fractionate deuterium differently. In aquatic systems, tracking trophic interactions is valuable for not only understanding the ecology of the system, but also for determining the degree of terrestrial input. The patterns of deuterium enrichment consistent within trophic levels is a useful tool for assessing the nature of these interactions in the environment.
The PSOE re-validated its 2004 triumph in the general election of March 2008, although it still did not reach the absolute majority. This time, Rodríguez Zapatero did not want to negotiate any support to achieve the investiture as President of the Government, so he was elected only with the votes of his party on April 11, 2008. In this second legislature, the economic outlook not only did not improve but worsened notably from September 2008 onwards as a consequence of the impact of the international crisis triggered by the bankruptcy of the US investment bank Lehman Brothers. Unemployment soared, initially in the construction sector – the Spanish property bubble also burst – and then in the rest of the sectors, with the emigrants being the most affected. The government, which found it difficult to recognize the seriousness of the crisis, responded with the implementation of economic policy measures typically Keynesian, among which stood out the Spanish Plan for the Stimulus of the Economy, better known as "Plan E" and approved by the end of 2008. However, GDP fell by 3.7% in 2009 and the unemployment rate exceeded 20% of the active population. As a consequence of the increase in spending to stimulate demand and the fall in revenues due to the recession, the public deficit soared to close to 10% of GDP.
==== Web-enabled ==== A web-enabled LIMS architecture is essentially a thick-client architecture with an added web browser component. In this setup, the client-side software has additional functionality that allows users to interface with the software through their device's browser. This functionality is typically limited only to certain functions of the web client. The primary advantage of a web-enabled LIMS is the end-user can access data both on the client side and the server side of the configuration. As in a thick-client architecture, updates in the software must be propagated to every client machine. However, the added disadvantages of requiring always-on access to the host server and the need for cross-platform functionality mean that additional overhead costs may arise.
In a small clinical trial in eighteen pediatric subjects with intractable weight gain following therapy for acute lymphoblastic leukemia or brain tumors and other evidence of hypothalamic dysfunction, octreotide reduced body mass index (BMI) and insulin response during glucose tolerance test, while increasing parent-reported physical activity and quality of life (QoL) relative to placebo. In a separate placebo-controlled trial of obese adults without known hypothalamic lesions, obese subjects who received long-acting octreotide lost weight and reduced their BMI compared to subjects receiving placebo; post hoc analysis suggested greater effects in participants receiving the higher dose of the medication, and among "Caucasian subjects having insulin secretion greater than the median of the cohort." "There were no statistically significant changes in QoL scores, body fat, leptin concentration, Beck Depression Inventory, or macronutrient intake", although subjects taking octreotide had higher blood glucose after a glucose tolerance test than those receiving placebo.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.